Approval · Notice of Compliance 20260 · 2018
LUPRON: Notice of Compliance 20260
Issued January 4, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20260
- Date
- January 4, 2018
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to product labelling to remove reference of alcohol swabs
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUPRON | Not yet assigned | — |
| LUPRON DEPOT | Not yet assigned | — |
Medicinal ingredients
- LEUPROLIDE ACETATE 5 MG per ML
- LEUPROLIDE ACETATE 3.75 MG per SYR
- LEUPROLIDE ACETATE 11.25 MG per SYR